The Androgen Receptor: Is It a Promising Target?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28766215.
- Also identified by DOI 10.1245/s10434-017-5961-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A growing body of literature supports the conclusion that the androgen receptor (AR) plays an important role in breast cancer pathogenesis and may prove to be a relevant therapeutic target for patients with AR-driven breast cancer. This has been most apparent in the subset of patients with triple-negative breast cancer (TNBC), in whom approximately 50% of tumors may have androgen dependence. Recent phase 2 clinical trials of agents that antagonize AR or reduce androgen production have shown clinical benefit and efficacy to varying degrees. This review highlights three of these recent trials of AR<sup>+</sup> TNBC and acknowledge ongoing research in this exciting area.
Medical subject headings
- Androgen Receptor Antagonists
- Breast Neoplasms
- Gene Expression Regulation, Neoplastic
- Receptors, Androgen